Table 2 BsAb combination therapies for B-cell lymphoma
BsAbs | Phase | Settings | N | Median number of prior lines of therapy | number of treatment cycles | Median follow-up (m) | ORR (%) | CR (%) | CRS Grade ≥ 3 (%) |
|---|---|---|---|---|---|---|---|---|---|
Epcoritamab + R2 [6] | I/II | RRFL | 56 | 1(1–9) | until PD or unacceptable toxicity | 4.0 | 95 | 73 | 0 |
Epcoritamab + R2 [7] | I/II | ND FL | 41 | - | until PD or unacceptable toxicity | 4.4 | 90 | 69 | 0 |
Epcoritamab + R‑DHAX/C [8] | I/II | RR DLBCL | 29 (15 with ASCT) | 1 | until PD or unacceptable toxicity | 9.2 | 100 (with ASCT) 64 (no ASCT) | 80 (with ASCT) 45 (no ASCT) | 0 |
Mosunetuzumab + Pola [9] | Ib/II | RR DLBCL | 60 | 3(1–8) | with a CR: Mosun was stopped after 8 cycles; PR or SD: Mosun could be continued for up to 17 cycles | 5.3 | 72 (age ≥ 65) 54 (age < 65) | 56 (age ≥ 65) 38 (age < 65) | 0 |
Glofitamab + RO7227166[10] | I | RR DLBCL | 46 | 3(1–7) | 12 cycles | 67 | 39 | 0 | |
RR FL | 24 | 91 | 73 | 0 | |||||
Glofitamab + R-CHOP [11] | Ib | ND DLBCL | 56 | - | 8 cycles | 5.6 | 93.5 | 76.1 | 0 |